4,5-bis(bromomethyl)-1,3-dioxol-2-one | 62458-19-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机碳酸及其衍生物
• 英文名称: 4,5-bis(bromomethyl)-1,3-dioxol-2-one
• 英文别名: 4,5-di(bromomethyl)-2-oxo-1,3-dioxole
• CAS: 62458-19-9
• 化学式: C₅H₄Br₂O₃
• 分子量: 271.893
• InChiKey: GZMPBWRVQSXAJR-UHFFFAOYSA-N

物化性质

• 熔点：
  57 °C(Solv: ethyl ether (60-29-7))
• 沸点：
  96 °C(Press: 0.0001 Torr)
• 密度：
  2.173±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4,5-bis(bromomethyl)-1,3-dioxol-2-one 在 盐酸 、 四丁基溴化铵 、 potassium carbonate 作用下， 以 三氯乙烯 、 乙酸乙酯 为溶剂， 反应 26.5h， 生成 (2-oxo-1,3-dioxole-4,5-diyl)bis(methylene) (1r,1'r,4r,4'r)-bis(4-(aminomethyl)cyclohexane-1-carboxylate) hydrochloride
  参考文献：
  名称：

  Tranexamic acid derivatives with enhanced absorption

  摘要：

  Derivatives of the antifibrinolytic drug tranexamic acid [trans-4-(aminomethyl)cyclohexanecarboxylic acid] containing one or two tranexamic acid moieties were synthesized. Most of the derivatives have good stability in acidic and neutral solutions but are easily hydrolyzed in plasma. By measuring the amount of tranexamic acid excreted in the urine after an oral dose, relative absorptions of a number of derivatives in the rat were estimated. Most of the derivatives showed greater absorption than tranexamic acid itself. 1-[(Ethoxycarbonyl)oxy]ethyl trans-4-(amino-methyl)cyclohexanecarboxylate hydrochloride was chosen for studies in man.

  DOI：

  10.1021/jm00154a004
• 作为产物：
  描述：

  4,5-二甲基-1,3-二氧杂环戊烯-2-酮 在 N-溴代丁二酰亚胺(NBS) 、 偶氮二异丁腈 作用下， 以 苯 为溶剂， 反应 2.0h， 以66%的产率得到4,5-bis(bromomethyl)-1,3-dioxol-2-one
  参考文献：
  名称：

  [EN] INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE
  [FR] INHIBITEURS D'INDOLÉAMINE 2,3-DIOXYGÉNASE ET LEURS PROCÉDÉS D'UTILISATION

  摘要：

  本发明提供了一种化合物，其化学式为(II)：一种吲哌酮胺2,3-二氧化酶（IDO）抑制剂，可用作治疗增生性疾病，如癌症、病毒感染和/或自身免疫疾病的药物。其前药也已被披露。

  公开号：

  WO2019136112A1

文献信息

• [EN] ANGIOTENSIN II RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DES RÉCEPTEURS DE L'ANGIOTENSINE II
  申请人：NICOX SA

  公开号：WO2010015447A1

  公开（公告）日：2010-02-11

  A compound having the structure (formula 1) wherein R is a "sartan family" moiety Z is a nitroxy carrying moiety, or a pharmaceutically acceptable salt thereof. The compounds are active against hypertension.

  一种具有结构（式1）的化合物，其中R是“沙坦家族”基团，Z是携带亚硝基的基团，或其药用盐。这些化合物对高血压具有活性。
• Bis-esters of 4,5-di(hydroxymethyl)-2-oxo-1,3-dioxole as antibacterial
  申请人：Pfizer Inc.

  公开号：US04434173A1

  公开（公告）日：1984-02-28

  Derivatives of 4,5-di(hydroxymethyl)-2-oxo-1,3-dioxole in which one hydroxy group has been esterified through the carboxy group of ampicillin or amoxicillin, and the other hydroxy group has been esterified through the carboxy group of sulbactam (penicillanic acid 1,1-dioxide), are useful as antibacterial agents. Certain novel compounds, which are useful as intermediates to the aforesaid antibacterial agents, are also disclosed.

  4,5-二(羟甲基)-2-氧代-1,3-二噁烷的衍生物，其中一个羟基已经通过氨苄青霉素或阿莫西林的羧基酯化，另一个羟基已经通过舒巴坦的羧基酯化（青霉素酸1,1-二氧化物），可用作抗菌剂。还披露了作为上述抗菌剂中间体的某些新化合物。
• [EN] HETEROCYCLIC ANTI-VIRAL COMPOUNDS COMPRISING METABOLIZABLE MOIETIES AND THEIR USES<br/>[FR] COMPOSES ANTIVIRAUX HETEROCYCLIQUES COMPORTANT DES GROUPES FONCTIONNELS METABOLISABLES ET LEURS UTILISATIONS
  申请人：RIGEL PHARMACEUTICALS INC

  公开号：WO2005097760A1

  公开（公告）日：2005-10-20

  The present invention relates to substituted prodrug and compositions thereof useful for treating or preventing Hepatitis C virus (HCV) infections. In particular, the present invention relates to prodrugs of substituted diphenyl-, diheteroaryl- and mixed phenyl heteroaryl substituted five-membered heterocycle compounds, compositions comprising the compounds and the use of such compounds and compositions to inhibit HCV replication and/or proliferation as a therapeutic approach towards the treatment and/or prevention of HCV infections in humans and animals.

  本发明涉及替代前药及其组合物，用于治疗或预防丙型肝炎病毒（HCV）感染。具体而言，本发明涉及替代二苯基、二杂环芳基和混合苯基杂环芳基替代的五元杂环化合物的前药，包含这些化合物的组合物以及利用这些化合物和组合物来抑制HCV复制和/或增殖作为治疗方法，以治疗和/或预防人类和动物中的HCV感染。
• Studies on prodrugs. VIII. Preparation and characterization of (5-methyl-2-oxo-1,3-dioxol-4-yl) methyl esters of sulbactam and its analogs.
  作者：SHOJI IKEDA、FUMIO SAKAMOTO、RYOICHI HIRAYAMA、YASUSHI TAKEBE、MIKIO SOTONURA、GORO TSUKAMOTO

  DOI：10.1248/cpb.36.218

  日期：——

  Several (5-methyl-2-oxo-1, 3-dioxol-4-yl)methyl esters of β-lactamase inhibitors were prepared and evaluated for oral absorbability. Sulbactam (5-methyl-2-oxo-1, 3-dioxol-4-yl)methyl ester (5a) was found to prodece a 5-fold higher serum level of sulbactam than sulbactam itself after oral administration to mice. The diester (15), in which ampicilling is bonded to the 5-methyl group of the above sulbactam ester (5a), was also prepared, but this diester (15) did not produce high serum levels of ampicillin and sulbactam after oral administration to mice.

  制备了几种β-内酰胺酶抑制剂的（5-甲基-2-氧代-1, 3-二氧戊环-4-基）甲酯，并对其口服吸收性进行了评估。研究发现，小鼠口服舒巴坦（5-甲基-2-氧代-1, 3-二氧戊环-4-基）甲酯（5a）后，血清中的舒巴坦含量比舒巴坦本身高 5 倍。还制备了二酯（15），其中氨苄西林与上述舒巴坦酯（5a）的 5-甲基键合，但这种二酯（15）在小鼠口服后产生的氨苄西林和舒巴坦血清浓度并不高。
• Mutual prodrugs of amlodipine and atorvastatin
  申请人：Pfizer Inc

  公开号：US06486182B1

  公开（公告）日：2002-11-26

  This invention relates to mutual prodrugs of amlodipine and atorvastatin and to pharmaceutical compositions thereof. This invention also relates to methods of treating angina pectoris, atherosclerosis, and hypertension and hyperlipidemia in a mammal using those prodrugs and compositions. This invention also relates to methods of managing cardiac risk in a mammal, including humans, presenting with symptoms of cardiac risk by administering those prodrugs and compositions.

  本发明涉及氨氯地平和阿托伐他汀的相互藥物前体及其制药组合物。本发明还涉及使用这些前体和组合物治疗哮喘性心绞痛、动脉硬化、高血压和高脂血症的哺乳动物的方法。本发明还涉及通过给予这些前体和组合物来管理哺乳动物（包括人类）的心脏风险的方法，这些哺乳动物呈现心脏风险症状。